Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 37 Carcinoma, Non-Small-Cell Lung 29 Triple Negative Breast Neoplasms 23 Nasopharyngeal Carcinoma 23 Stomach Neoplasms 21 Esophageal Squamous Cell Carcinoma 19 Esophageal Neoplasms 19 Breast Neoplasms 18 Squamous Cell Carcinoma of Head and Neck 14 Uterine Cervical Neoplasms 12 Colorectal Neoplasms 12 Sarcoma 10 Pancreatic Neoplasms 9 Lung Neoplasms 9 Recurrence 7 Neoplasm Metastasis 7 Melanoma 6 Hodgkin Disease 6 Cholangiocarcinoma 6 Liver Neoplasms 5 Biliary Tract Neoplasms 5 Small Cell Lung Carcinoma 4 Osteosarcoma 4 Neoplasms 4 Advanced Solid Tumor 4 Advanced Gastric Cancer 4 Solid Tumor 3 Respiratory Tract Diseases 3 Rectal Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

trifluridine tipiracil drug combination 1 camrelizumab 1 anlotinib 1 Radiotherapy 1 Induction Chemotherapy 1 Immunotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × ESCC × camrelizumab × Clear all

NCT05050760 2023-01-31

DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer

Xijing Hospital

Phase NA Unknown

ESCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡